Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.69 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.69 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166101 | 0.93 | PTGDR2 (0.80) | PTGDR2PTGDRPPARAPPARGMMP13 | |
| SCHEMBL3166216 | 0.89 | PTGDR2 (0.86) | PTGDR2PTGDRMMP13CYSLTR2CYSLTR1 | |
| SCHEMBL3159782 | 0.87 | PTGDR2 (0.51) | PTGDR2PTGDRFAAHCYSLTR2CYSLTR1 | |
| SCHEMBL3168806 | 0.85 | PTGDR2 (0.71) | PTGDR2PTGDRPPARAPPARGMMP13 | |
| SCHEMBL12678714 | 0.84 | PTGDR2 (0.80) | PTGDR2PTGDRPPARAPPARG | |
| SCHEMBL3165589 | 0.83 | PTGDR2 (0.65) | PTGDR2PTGDRMMP13FAAHCYSLTR2 | |
| SCHEMBL3159589 | 0.82 | PTGDR2 (0.59) | PTGDR2PTGDRMMP13FAAHCYSLTR2 | |
| SCHEMBL3174515 | 0.82 | PTGDR2 (0.65) | PTGDR2PTGDR | |
| SCHEMBL3176547 | 0.82 | PTGDR2 (1.00) | PTGDR2PTGDRMMP13CYSLTR2CYSLTR1 | |
| SCHEMBL3176587 | 0.78 | PTGDR2 (0.59) | PTGDR2PTGDRMMP13FAAHCYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PTGDR2 116/4885PTGDR 189/4885PPARA 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.